Hanmi Pharmaceutical has been recognized as an 'Innovation Leader' in a global academic journal evaluation, demonstrating its research and development (R&D) competitiveness.
On July 6, Hanmi Pharmaceutical announced that it was included in the 'Innovation Leader' group in an analysis of emerging pharmaceutical and biotech companies published by the international journal 'Nature Reviews Drug Discovery.'
The study analyzed R&D productivity over 15 years, from 2010 to 2025, for 45 pharmaceutical and biotech companies in Asia, Latin America, Eastern Europe, the Middle East, and Africa (EEMEA). It evaluated companies with revenues exceeding $500 million based on their R&D investment ratios, clinical pipeline compositions, and sales.
The researchers classified companies into three categories: Innovation Leaders, Emerging Innovators, and Generic Companies. Hanmi Pharmaceutical earned its place in the top tier due to its focus on innovative drug strategies and high R&D productivity.
Hanmi stated, "Despite having a relatively low investment ratio of about 17% of sales compared to other innovation leaders, our high productivity was noted based on the proportion of innovative drug pipelines and global technology export achievements." This highlights the effectiveness of a 'performance-oriented' R&D strategy rather than just investment size.
The paper highlighted Hanmi as a representative example of a company that has shifted its focus to innovation in metabolic and rare diseases. The researchers predicted that Asian innovative pharmaceutical companies, particularly from Korea and China, will emerge as strong competitors to U.S. and European firms in the future.
Hanmi invests a double-digit percentage of its annual revenue in R&D, focusing on obesity, metabolic diseases, cancer, and rare diseases. The company is enhancing its global competitiveness through its proprietary platform technology and open innovation strategies.
Choi In-young, Vice President and Head of Future Growth at Hanmi Pharmaceutical, remarked, "This evaluation is significant as it recognizes our strategy and achievements centered on innovative drugs in terms of R&D productivity, not just investment size. We will continue to strengthen our global competitiveness through differentiated drug development."
In addition, Hanmi Pharmaceutical has completed the acquisition of Canadian biotech company Aptose Biosciences, securing a North American R&D base. The total investment for the acquisition, including a previous loan of 56.8 billion won to Aptose, amounts to 70 billion won. With this acquisition finalized, Hanmi will directly lead the global development of its internally developed drug, Tuspetyinib.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.